Policy Issues in the Clinical Development and Use of Predictive Biomarkers for Molecular Targeted Therapies

  • V. M. PrattEmail author


The policy issues for the development, validation, and clinical implementation of predictive biomarkers for molecularly targeted therapies present a number of challenges. First, there is significant uncertainty in the current regulatory framework for biomarker tests for molecularly targeted therapies. Second, there is concern over the adequacy of the current oversight of laboratories conducting biomarker testing. Third, there is a lack of alignment between the processes for regulatory and reimbursement decisions. All these challenges cause uncertainty and confusion among clinicians, patients, test manufacturers, and payers.


Policy US Food and Drug Administration (FDA) Centers for Medicare and Medicaid Services (CMS) Laboratory-developed procedures (LDPs) Medicare Administrative Contractors (MACs) Companion diagnostics Clinical Laboratory Improvement Amendment (CLIA) of 1988 



Medicare Administrative Contractors (MACs)

Contracted private healthcare insurers that process medical claims for Medicare beneficiaries


  1. 1.
    Graig LA, Phillips JK, Moses HL, editors. Biomarker tests for molecularly targeted therapies: key to unlocking precision medicine. Washington, DC: The National Academy of Science; 2017. Accessed 4/25/2017.Google Scholar
  2. 2.
    U.S. Food & Drug Administration (FDA). 510(k) clearances. 2017. Accessed 4/25/2017.
  3. 3.
    U.S. Food & Drug Administration (FDA). Is the product a medical device? 2014. Accessed 4/25/2017.
  4. 4.
    U.S. Food & Drug Administration (FDA). Draft guidance for industry, food and drug administration staff, and clinical laboratories: framework for regulatory oversight of Laboratory Developed Tests (LDTs). 2014. Accessed 4/25/2017.
  5. 5.
    U.S. Food & Drug Administration (FDA). Discussion paper on Laboratory Developed Tests (LDTs). 2017. Accessed 4/25/2017.
  6. 6.
    U.S. Food & Drug Administration (FDA). Companion diagnostics. 2016. Accessed 4/25/2017.
  7. 7.
    Frueh FW. Regulation, reimbursement, and the long road of implementation of personalized medicine – a perspective from the United States. Value Health. 2013;16(6 Suppl):S27–31.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Cohen J, Felix A. Personalized medicine’s bottleneck: diagnostic test evidence and reimbursement. J Personalized Med. 2014;4(2):163–75.CrossRefGoogle Scholar
  9. 9.
    Mansfield EA. FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res. 2014;20:1453–7.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    IOM. Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies: workshop summary. Washington, DC: National Academies Press; 2015.Google Scholar
  11. 11.
    UK Department of Health Pathology Modernisation Team. Modernising pathology services. 60–70% of NHS patients’ diagnoses depend on laboratory tests, 2004. p. 7. Available at
  12. 12.
    Centers for Medicare & Medicaid Services (CMS). Details for title: CMS-1524-FC. 2012. Accessed 4/25/2017.
  13. 13.
    Graf M, Needham D, Teed N, Brown T. Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers. Pers Med. 2013;10(3):235.CrossRefGoogle Scholar
  14. 14.
    Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers’ coverage of personalized medicine. J Oncol Pract. 2011;7(3 Suppl):18s–24s.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Chambers JD, Chenoweth M, Thorat T, Neumann PJ. Private payers disagree with medicare over medical device coverage about half the time. Health Aff. 2015;34(8):1376–82.CrossRefGoogle Scholar
  16. 16.
    Federal Register: The Daily Journal of the United States Government. Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2017; Medicare Advantage Bid Pricing Data Release; Medicare Advantage and Part D Medical Loss Ratio Data Release; Medicare Advantage Provider Network Requirements; Expansion of Medicare Diabetes Prevention Program Model; Medicare Shared Savings Program Requirements. 2016. Accessed 4/25/2017.
  17. 17.
    Palmetto GBA. MoIDX ®. 2017. Accessed 4/25/2017.
  18. 18.
    McKesson Diagnostics Exchange. McKesson Z-Code™ Identifiers. Accessed 4/25/2017.
  19. 19.
    Federal Register: The Daily Journal of the United States Government. Program for Parallel Review of Medical Devices. 2016. Accessed 4/25/2017.
  20. 20.
    Messner DA, Tunis SR. Current and future state of FDA-CMS parallel reviews. Clin Pharmacol Ther. 2012;91(3):383–5.CrossRefGoogle Scholar
  21. 21.
    Ginsburg GS, Kuderer NM. Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. J Clin Oncol. 2012;30(34):4233–42.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisUSA

Personalised recommendations